CA Patent

CA2781061A1 — Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom

Assigned to Medicinova Inc · Expires 2011-05-26 · 15y expired

What this patent protects

The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method inc…

USPTO Abstract

The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.

Drugs covered by this patent

Patent Metadata

Patent number
CA2781061A1
Jurisdiction
CA
Classification
—
Expires
2011-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Medicinova Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.